Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
The now up | Sirpeter | investorshub | 09/19/2023 10:03:10 AM |
$OKYO The now up | Sirpeter | investorshub | 09/19/2023 9:16:28 AM |
Price gaining up | Count Crypto | investorshub | 09/19/2023 9:01:29 AM |
$OKYO bears are running | mfayman | investorshub | 09/19/2023 8:02:49 AM |
bears and bulls | glenn1919 | investorshub | 09/19/2023 5:25:48 AM |
short squeeze all day | mfayman | investorshub | 09/19/2023 4:30:17 AM |
$OKYO Good news recently, we should start to see this one move | Count Crypto | investorshub | 09/19/2023 3:09:21 AM |
what do you make of this data? | Pisd | investorshub | 09/19/2023 2:30:56 AM |
$OKYO MomentumIts gaining last trade up | Sirpeter | investorshub | 09/19/2023 1:59:09 AM |
$OKYO bulls and bears | Ryguy008 | investorshub | 09/19/2023 1:35:58 AM |
$OKYO Price now | Count Crypto | investorshub | 09/19/2023 12:31:51 AM |
$OKYO Price gaining | StocksNcash | investorshub | 09/18/2023 11:31:11 PM |
MomentumIts gaining up | Boris the Spider | investorshub | 09/18/2023 11:10:59 PM |
MomentumIts gaining | Anita Dump | investorshub | 09/18/2023 9:54:40 PM |
$OKYO MomentumIts trading last trade up | Count Crypto | investorshub | 09/18/2023 8:34:07 PM |
$OKYO MomentumIts now last trade up | Count Crypto | investorshub | 09/18/2023 7:15:59 PM |
$OKYO bears are running | Count Crypto | investorshub | 09/18/2023 6:55:19 PM |
oh yeah news for the day | Anita Dump | investorshub | 09/18/2023 5:54:38 PM |
$OKYO What do you make of this? | Boris the Spider | investorshub | 09/18/2023 5:50:34 PM |
$OKYO and the shorts continue | Sirpeter | investorshub | 09/18/2023 5:06:25 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...